CH BIOTECH SER Anticipates 60% Reduction in Net Loss for 2025 Fiscal Year

Stock News03-06

CH BIOTECH SER (08037) has announced an expectation that the group will record a net loss of no more than HK$100 million for the year ending December 31, 2025. This represents a decrease of approximately 60% compared to the net loss of HK$252 million reported for the year ending December 31, 2024.

The significant improvement anticipated for the 2025 fiscal year is primarily attributed to several factors. These include (i) insurance compensation income of approximately HK$14 million received in the 2025 fiscal year for damages caused by heavy rain to a construction site in Hainan during the 2024 fiscal year; (ii) a reduction in research and development costs within the immunotherapy segment; (iii) the successful implementation of cost-control measures leading to lower administrative expenses; and (iv) a one-time impairment loss on property, plant, equipment, and intangible assets that was recognized in the 2024 fiscal year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173165966?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 20:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173165966","market":"sh","top_or_hot":-1,"title":"CH BIOTECH SER Anticipates 60% Reduction in Net Loss for 2025 Fiscal Year","media":"Stock News","content":"<p>CH BIOTECH SER (08037) has announced an expectation that the group will record a net loss of no more than HK$100 million for the year ending December 31, 2025. This represents a decrease of approximately 60% compared to the net loss of HK$252 million reported for the year ending December 31, 2024.</p>\n<p>The significant improvement anticipated for the 2025 fiscal year is primarily attributed to several factors. These include (i) insurance compensation income of approximately HK$14 million received in the 2025 fiscal year for damages caused by heavy rain to a construction site in Hainan during the 2024 fiscal year; (ii) a reduction in research and development costs within the immunotherapy segment; (iii) the successful implementation of cost-control measures leading to lower administrative expenses; and (iv) a one-time impairment loss on property, plant, equipment, and intangible assets that was recognized in the 2024 fiscal year.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CH BIOTECH SER Anticipates 60% Reduction in Net Loss for 2025 Fiscal Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCH BIOTECH SER Anticipates 60% Reduction in Net Loss for 2025 Fiscal Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-06 20:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CH BIOTECH SER (08037) has announced an expectation that the group will record a net loss of no more than HK$100 million for the year ending December 31, 2025. This represents a decrease of approximately 60% compared to the net loss of HK$252 million reported for the year ending December 31, 2024.</p>\n<p>The significant improvement anticipated for the 2025 fiscal year is primarily attributed to several factors. These include (i) insurance compensation income of approximately HK$14 million received in the 2025 fiscal year for damages caused by heavy rain to a construction site in Hainan during the 2024 fiscal year; (ii) a reduction in research and development costs within the immunotherapy segment; (iii) the successful implementation of cost-control measures leading to lower administrative expenses; and (iv) a one-time impairment loss on property, plant, equipment, and intangible assets that was recognized in the 2024 fiscal year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"08037","symbol_name":"中国生物科技服务","start_time":0,"source_url":"","article_id":"1173165966","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173165966","pubTimestamp":1772801061,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CH BIOTECH SER (08037) has announced an expectation that the group will record a net loss of no more than HK$100 million for the year ending December 31, 2025. This represents a decrease of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"08037":"中国生物科技服务","BK1219":"保健护理服务","BK1511":"疑似财技股"},"translate_title":"CH BIOTECH SER预计2025财年净亏损减少60%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"08037":1},"content_text":"CH BIOTECH SER (08037) has announced an expectation that the group will record a net loss of no more than HK$100 million for the year ending December 31, 2025. This represents a decrease of approximately 60% compared to the net loss of HK$252 million reported for the year ending December 31, 2024.\nThe significant improvement anticipated for the 2025 fiscal year is primarily attributed to several factors. These include (i) insurance compensation income of approximately HK$14 million received in the 2025 fiscal year for damages caused by heavy rain to a construction site in Hainan during the 2024 fiscal year; (ii) a reduction in research and development costs within the immunotherapy segment; (iii) the successful implementation of cost-control measures leading to lower administrative expenses; and (iv) a one-time impairment loss on property, plant, equipment, and intangible assets that was recognized in the 2024 fiscal year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173165966","isCrawlerRequest":true}